Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma according to baseline status: Subset analyses of the phase III Sorafenib Asia-Pacific trial
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Cheng, Ann-Lii | - |
dc.contributor.author | Guan, Zhongzhen | - |
dc.contributor.author | Chen, Zhendong | - |
dc.contributor.author | Tsao, Chao-Jung | - |
dc.contributor.author | Qin, Shukui | - |
dc.contributor.author | Kim, Jun Suk | - |
dc.contributor.author | Yang, Tsai-Sheng | - |
dc.contributor.author | Tak, Won Young | - |
dc.contributor.author | Pan, Hongming | - |
dc.contributor.author | Yu, Shiying | - |
dc.contributor.author | Xu, Jianming | - |
dc.contributor.author | Fang, Fang | - |
dc.contributor.author | Zou, Jessie | - |
dc.contributor.author | Lentini, Giuseppe | - |
dc.contributor.author | Voliotis, Dimitris | - |
dc.contributor.author | Kang, Yoon-Koo | - |
dc.date.accessioned | 2021-09-06T17:52:48Z | - |
dc.date.available | 2021-09-06T17:52:48Z | - |
dc.date.created | 2021-06-18 | - |
dc.date.issued | 2012-07 | - |
dc.identifier.issn | 0959-8049 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/107960 | - |
dc.description.abstract | Background: The phase III Sorafenib Asia-Pacific (AP) trial-conducted in China, Taiwan and South Korea - confirmed that sorafenib improves overall survival (OS) and is safe for patients with advanced hepatocellular carcinoma (HCC). We performed a series of exploratory subset analyses to determine whether baseline status affected response to sorafenib. Methods: In the Sorafenib AP trial, 226 patients with well-preserved liver function (>95% Child-Pugh A) were randomised 2: 1 to sorafenib 400 mg bid or matching placebo. Subanalyses were based on aetiology (hepatitis B virus present/absent); tumour burden (macroscopic vascular invasion and/or extrahepatic spread present/absent); presence or absence of either lung or lymph node metastasis at baseline, Eastern Cooperative Oncology Group performance status (0, 1-2); serum concentrations of alanine aminotransferase/aspartate aminotransferase (normal, mildly elevated, moderately elevated), alpha-fetoprotein (normal/elevated) and total bilirubin (normal/elevated); and whether or not there was a history of hepatectomy or transarterial chemoembolisation/embolisation. Subgroup assessments included OS, time to progression (TTP), disease control rate and safety. Findings: Sorafenib consistently improved both median OS and median TTP, compared with placebo (range of hazard ratios (HR), 0.32-0.87 and 0.31-0.75, respectively). The most common grade 3/4 adverse events were hand-foot skin reaction, diarrhoea and fatigue, the incidence of which was similar between subgroups. Interpretation: The efficacy and safety profiles of sorafenib in the subpopulations described were comparable with those in the overall study population. These exploratory analyses suggest that sorafenib is effective for patients from the AP region with advanced HCC, irrespective of baseline status. (C) 2011 Elsevier Ltd. All rights reserved. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | ELSEVIER SCI LTD | - |
dc.subject | HEPATITIS-B-VIRUS | - |
dc.subject | RAF/MEK/ERK PATHWAY | - |
dc.subject | TUMOR PROGRESSION | - |
dc.subject | STAGING SYSTEMS | - |
dc.subject | PROGNOSIS | - |
dc.subject | SUBANALYSIS | - |
dc.subject | EXPRESSION | - |
dc.subject | APOPTOSIS | - |
dc.subject | TARGETS | - |
dc.subject | ALPHA | - |
dc.title | Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma according to baseline status: Subset analyses of the phase III Sorafenib Asia-Pacific trial | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Kim, Jun Suk | - |
dc.identifier.doi | 10.1016/j.ejca.2011.12.006 | - |
dc.identifier.scopusid | 2-s2.0-84862776817 | - |
dc.identifier.wosid | 000305278600005 | - |
dc.identifier.bibliographicCitation | EUROPEAN JOURNAL OF CANCER, v.48, no.10, pp.1452 - 1465 | - |
dc.relation.isPartOf | EUROPEAN JOURNAL OF CANCER | - |
dc.citation.title | EUROPEAN JOURNAL OF CANCER | - |
dc.citation.volume | 48 | - |
dc.citation.number | 10 | - |
dc.citation.startPage | 1452 | - |
dc.citation.endPage | 1465 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Oncology | - |
dc.relation.journalWebOfScienceCategory | Oncology | - |
dc.subject.keywordPlus | HEPATITIS-B-VIRUS | - |
dc.subject.keywordPlus | RAF/MEK/ERK PATHWAY | - |
dc.subject.keywordPlus | TUMOR PROGRESSION | - |
dc.subject.keywordPlus | STAGING SYSTEMS | - |
dc.subject.keywordPlus | PROGNOSIS | - |
dc.subject.keywordPlus | SUBANALYSIS | - |
dc.subject.keywordPlus | EXPRESSION | - |
dc.subject.keywordPlus | APOPTOSIS | - |
dc.subject.keywordPlus | TARGETS | - |
dc.subject.keywordPlus | ALPHA | - |
dc.subject.keywordAuthor | Hepatocellular carcinoma | - |
dc.subject.keywordAuthor | Sorafenib | - |
dc.subject.keywordAuthor | Subset analyses | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.